AbbVie Inc. said it is collaborating with non-profit biomedical research and drug discovery institute Scripps Research to develop potential new antiviral treatments for Covid-19.
SEONGNAM, South Korea and SAN DIEGO, Calif., Feb. 7, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for inflammation, fibrosis and oncology, and Scripps Research, an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index, today announced a research collaboration to discover and characterize novel reactive groups that target non-cysteine residues to uncover new druggable sites in targets of high therapeutic value.
Seven Bridges, the industry-leading bioinformatics ecosystem provider, and Scripps Research have been awarded a $7.5M contract to develop a federated data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID) under a project titled the NIAID Data Ecosystem (NDE). The NDE will be a secure environment to find, access, query and analyze data from select NIAID repositories, knowledge bases and other relevant resources. The NDE is intended to serve as a place to discover and analyze data on a wide range of infectious diseases inclusive of emerging and re-emerging diseases including COVID-19 – with a keen eye towards ensuring scalability and rapid response to future pandemics.
The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s board switched to a radically different strategy: They sold themselves for an undisclosed amount to a syndicate of Chinese investors and pharma companies.
Scripps Research Institute has settled a case with the Justice Department alleging claims of misappropriated funds, the US attorney for the district of Maryland announced late last week.